<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195689</url>
  </required_header>
  <id_info>
    <org_study_id>M02-537</org_study_id>
    <nct_id>NCT00195689</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis</brief_title>
  <official_title>A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the long-term safety and clinical efficacy of
      adalimumab in treatment of moderate to severely active psoriatic arthritis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR 20/50/70</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PsARC</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>HAQ</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>FACTIT Fatigue Scale</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease progression measurements</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response indicators</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human anti-TNF monoclonal antibody/adalimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed study M02-518 or M02-570

        Exclusion Criteria:

          -  Subject prematurely discontinued study M02-518 or M02-570

               -  Female subject who is pregnant or breast-feeding or considering becoming pregnant

               -  Subject considered by the investigator, for any reason, to be an unsuitable
                  candidate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Paperiello</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Medical Information-Abbott Laboratories</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 28, 2007</last_update_submitted>
  <last_update_submitted_qc>August 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

